-

Mindpeak and Sagis Diagnostics to launch Collaborative Study on AI-Enhanced Detection of Nail Mycosis

original Mindpeak and Sagis Diagnostics to launch Collaborative Study on AI-Enhanced Detection of Nail Mycosis. (Photo: Business Wire)

Mindpeak and Sagis Diagnostics to launch Collaborative Study on AI-Enhanced Detection of Nail Mycosis. (Photo: Business Wire)

HAMBURG, Germany & HOUSTON--(BUSINESS WIRE)--Mindpeak, GmbH, the leader in AI-powered pathological solutions, today announced the collaboration with Sagis DX to conduct a spearheading study, assessing the efficacy of the new Mindpeak Onychomycosis AI algorithm.

This innovative technology has potential to revolutionize the detection of onychomycosis on PAS-stained whole slide images, showcasing the transformative power of AI in the field of pathology.

The Mindpeak Onychomycosis AI algorithm is designed to automate the process of detecting hyphae from multiple slides, by efficiently identifying target structures that may appear sparsely in whole-slide images. The algorithm aims to reduce the risk of missed diagnoses.

"We are thrilled to embark on this collaborative study with Sagis Diagnostics," said Felix Faber, CEO of Mindpeak. "This research will not only showcase the capabilities of our Onychomycosis AI, but also highlight its potential to streamline workflows, save time, and improve patient care through more accurate diagnoses."

About Mindpeak

Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak's platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care. For more information, visit www.mindpeak.ai, Twitter, and LinkedIn.

About Sagis Diagnostics

Sagis Diagnostics is an entirely physician-led pathology group backed by a CLIA and CAP-accredited histology laboratory. With board-certified and subspecialty-trained pathologists always within reach, we deliver the highest quality services to physicians, physician groups, ambulatory surgery centers, and hospitals. Our commitment to quality and excellence is built upon our expertise and the utilization of the latest diagnostic tools. Providing accurate, prompt, and clear diagnoses in a personal and customizable manner, we prioritize our referring physicians' needs. As a patient-centric facility, we strive to deliver the best medical care possible. For more information, visit SagisDx.com.

Contacts

Mindpeak GmbH
Katja Eisele
Email: katja.eisele@mindpeak.ai

Industry:

Mindpeak

Release Versions
English

Contacts

Mindpeak GmbH
Katja Eisele
Email: katja.eisele@mindpeak.ai

More News From Mindpeak

Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca

HAMBURG, Germany--(BUSINESS WIRE)--The collaboration aims to assess the transformative potential of AI in digital pathology, with a specific focus on accelerating primary breast cancer diagnosis. Breast cancer remains one of the leading causes of cancer-related deaths in women worldwide. Early and accurate diagnosis is essential for significantly improving clinical outcomes and patient survival rates. However, this process is often hindered by a limited pathology workforce and time-consuming ca...

ZEISS and Mindpeak partner to advance Multiplex Immunofluorescence (mIF) solutions for pathology

HAMBURG, Germany--(BUSINESS WIRE)--ZEISS partners with Mindpeak, a pioneer in AI-powered pathology solutions, to develop an integrated Multiplex Immunofluorescence (mIF) solution that serves pathologists across research, diagnostics, and clinical applications. Mindpeak’s expertise in AI-based image analysis of pathological tissues, particularly through its established algorithms for clinical routine applications, complements ZEISS's advanced instruments and software for research applications of...

Mindpeak secures $15.3M in series A funding to accelerate growth in AI-based digital pathology

HAMBURG, Germany--(BUSINESS WIRE)--Mindpeak, the leader in AI-powered pathological solutions, today announced it has raised $15.3 million in a Series A funding round. The round was led by ZEISS Ventures and InnoVentureFund with participation from - amongst others - AI.FUND and the European Innovation Council Fund. While Mindpeak has a cash-flow positive core business, this new investment will enable the company to further expand the commercialisation of its pioneering technologies across severa...
Back to Newsroom